Skip to main
AARD
AARD logo

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics Inc. is well-positioned for future growth due to its innovative approach in developing ARD-101, a novel therapeutic targeting a significant unmet need in treating hyperphagia associated with Prader-Willi Syndrome (PWS). The company’s focus on activating Bitter Taste Receptors (TAS2Rs) in the gut may allow for more effective treatment options compared to existing therapies, as it triggers the release of multiple hormones linked to the hyperphagia pathway. Projections estimate ARD-101 could achieve worldwide sales of $1.5 billion by 2033, reflecting strong market potential and anticipated uptake in a space with considerable demand for improved therapeutic solutions.

Bears say

Aardvark Therapeutics Inc faces significant challenges as it progresses into a Phase 3 clinical trial for its product candidate ARD-101, primarily due to the limitations of its Phase II data, which was derived from a small sample size of 18 patients and generated results from an open-label study design. The potential for inflated screening responses due to caregiver bias raises concerns about the reliability of the reported efficacy metrics, particularly regarding the HQ-CT scores. Furthermore, while the minimal oral bioavailability of ARD-101 suggests low safety concerns, the incomplete understanding of its safety profile, combined with the critical nature of hyperphagia in patient care, compounds the uncertainties surrounding the drug's market viability.

AARD has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 5 analysts, AARD has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.